Podcast appearances and mentions of john p leonard

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

In this episode, Julie M. Vose, MD, MBA;  Brad S. Kahl, MD; and  John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on: Follicular lymphomaMarginal zone lymphomaMantle cell lymphomaDiffuse large B-cell lymphomaPosttransplant lymphoproliferative disorderPresenters:Julie M. Vose, MD, MBAChief, Division of Oncology and HematologyNeumann M. and Mildred E. Harris ProfessorDepartment of Internal MedicineUniversity of Nebraska Medical CenterOmaha, NebraskaBrad S. Kahl, MDProfessor of MedicineDepartment of Medical OncologyWashington University School of MedicineSt Louis, MissouriJohn P. Leonard, MDRichard T. Silver Distinguished Professor of Hematology and Medical OncologyProfessor of MedicineWeill Cornell MedicineNew York Presbyterian HospitalNew York, New YorkLink to the complete program, including downloadable slidesets, expert commentaries, an on-demand webcast, and treatment resource guides:https://bit.ly/3tb47wU

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Follicular Lymphoma — Faculty Presentation 2: Novel and Investigational Agents and Strategies for FL – John P Leonard, MD CME information and select publications

John P. Leonard, MD, Weill Cornell Medicine, New York Presbyterian, New York, NY Recorded on December 16, 2021 As 2021 comes to a close, the COVID-19 pandemic continues to evolve. In this episode, Dr. John Leonard, from Weill Cornell Medicine, New York Presbyterian Hospital, discusses the latest updates on how COVID-19 affects the blood cancer patient population. What is the value of the vaccine in blood cancer patients who are on treatment that diminishes immune response? What are the risks and benefits of an mRNA vaccine? What does treatment look like in both symptomatic and asymptomatic patients? How are we seeing the Omicron variant affecting this? Tune in to this important discussion today!

Proceedings from the sixth in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Stephen M Ansell, Carla Casulo and John P Leonard on cases from the practices of Ms Jacklyn Gideon, Ms Robin Klebig and Ms Mollie Moran, including the following topics: Introduction (0:00) Case: A woman in her late 20s with Hodgkin lymphoma — Mollie Moran, APRN-CNP, AOCNP (10:39) Case: A man in his mid-70s with newly diagnosed follicular lymphoma — Robin Klebig, APRN, CNP, AOCNP (29:55) Case: A woman in her early 80s with relapsed diffuse large B-cell lymphoma (DLBCL) — Ms Klebig (52:58) Case: A woman in her mid-60s with relapsed DLBCL — Jacklyn Gideon, MSN, AGPCNP-BC (57:54) Case: A man in his early 70s with relapsed mantle cell lymphoma — Ms Gideon (1:15:26) NCPD information and select publications

A special audio program developed from the sixth in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Stephen M Ansell, Carla Casulo and John P Leonard on cases from the practices of Ms Jacklyn Gideon, Ms Robin Klebig and Ms Mollie Moran.

Proceedings from part 2 of a 4-part webinar series. Featuring perspectives from Drs John Kuruvilla, John P Leonard and Michael E Williams, including the following topics: Introduction (0:00) Evolving treatment paradigm for patients with diffuse large B-cell lymphoma (DLBCL) (3:33) Optimal management of newly diagnosed and relapsed/refractory follicular lymphoma (16:36) Available and emerging approach for mantle cell lymphoma (29:47) Selection and sequencing of therapies for patients with advanced Hodgkin lymphoma (40:55) Advances in chimeric antigen receptor T-cell therapy for DLBCL and other lymphoma subtypes (50:23) CME information and select publications

Proceedings from part 2 of a 4-part webinar series. Featuring perspectives from Drs John Kuruvilla, John P Leonard and Michael E Williams, moderated by Dr Neil Love.

Proceedings from part 4 of a 4-part webinar series during the 62nd ASH Annual Meeting. Featuring perspectives from Drs Jonathan W Friedberg, John Kuruvilla, Ann S LaCasce, John P Leonard and Michael E Williams, moderated by Dr Neil Love.

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Hodgkin and Non-Hodgkin Lymphoma — Faculty Presentation 3: Optimal Management of Newly Diagnosed and Relapsed/Refractory Follicular Lymphoma — Dr Leonard. CME information and select publications

Featuring perspectives from Drs Jonathan W Friedberg, John Kuruvilla, Ann S LaCasce, John P Leonard and Michael E Williams on the following topics: Introduction (0:00) Evolving treatment paradigm for patients with diffuse large B-cell lymphoma (DLBCL) – Dr LaCasce (2:24) Optimal management of newly diagnosed and relapsed/refractory follicular lymphoma – Dr Leonard (18:51) Available and emerging approaches for mantle cell lymphoma – Dr Williams (42:40) Selection and sequencing of therapies for patients with advanced Hodgkin lymphoma – Dr Kuruvilla (59:16) Advances in chimeric antigen receptor T-cell therapy for DLBCL and other lymphoma subtypes – Dr Friedberg (1:14:41) CME information and select publications

For this special edition of Oncology Today, Dr Neil Love discusses recently published and emerging research in follicular lymphoma with Drs Carla Casulo from the University of Rochester Wilmot Cancer Center and John P Leonard from the Weill Medical College of Cornell. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayFL20).

Featuring a roundtable discussion on recent data and optimal management of follicular lymphoma with Drs Carla Casulo and John P Leonard moderated by Neil Love, MD.

A roundtable discussion with Drs Carla Casulo and John P Leonard on recent developments in the treatment of follicular lymphomas, including the following topics: Current management of newly diagnosed follicular lymphoma (FL); choice of observation versus rituximab monotherapy (00:00) Association between vitamin D insufficiency and outcomes for patients with FL   5m41s Efficacy and tolerability of obinutuzumab/bendamustine for patients with newly diagnosed FL (9:44) Activity of lenalidomide/rituximab (R2) in patients with FL (15:56) Biology of FL; criteria for initiating therapy after diagnosis (20:55) Results of the Phase III GALLIUM study of obinutuzumab or rituximab, each in combination with chemotherapy, followed by maintenance obinutuzumab or rituximab for patients with untreated, advanced FL (31:02) Phase III RELEVANCE trial evaluating R2 versus rituximab/chemotherapy, each followed by maintenance rituximab, as first-line therapy for advanced FL (34:58) Selection and sequencing of therapies for relapsed/refractory FL; management of early progression of disease (41:07) Biologic predictors of early relapse; role of transplant for patients with FL (47:20) Activity and tolerability of CAR (chimeric antigen receptor) T-cell therapies for FL (54:39) Response to the PI3 kinase inhibitor umbralisib in combination with obinutuzumab for relapsed FL (58:02) Outcomes for patients with early relapse of FL in the National LymphoCare Study (1:04:35) Integration of the PI3 kinase inhibitors idelalisib, copanlisib and duvelisib into the management of FL (1:12:18) Mechanism of action, efficacy and tolerability of the recently approved EZH2 inhibitor tazemetostat for relapsed/refractory FL (1:22:01) Results of the Phase II ZUMA-5 study of axicabtagene ciloleucel for patients with relapsed/refractory indolent non-Hodgkin lymphoma (1:26:32) Biologic rationale for the use of the novel bispecific antibody mosunetuzumab for relapsed/refractory FL (1:30:40) Novel agents and approaches under investigation for patients with FL (1:34:58) CME information and select publications

Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting

Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting

Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting

Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting

Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting

Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting

Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting

Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting

A presentation on follicular lymphoma featuring perspectives from Dr John P Leonard. Introduction Program Overview: Dr Leonard (00:00) Optimizing the Care of Patients with Newly Diagnosed Follicular Lymphoma (FL) Initiation of active therapy versus watchful waiting; indications for rituximab monotherapy (00:34) Choice of systemic therapy for patients requiring treatment; impact of age, tumor bulk and symptomatology (3:55) Clinical research data evaluating maintenance therapy; factors influencing its use (15:41) Data for and clinical role of subcutaneous rituximab (20:29) Management of Relapsed/Refractory (R/R) FL Factors affecting the sequencing of systemic therapy for R/R disease (eg, previous treatment received, remission duration, symptomatology) (22:37) Integration of obinutuzumab in the R/R setting (25:50) Role of lenalidomide/rituximab in the management of R/R FL (28:54) Available clinical research data with the FDA-approved PI3K inhibitors (34:41) CME information and select publications

Proceedings from Part 3 of a 3-part satellite symposia series during the 2018 Pan Pacific Lymphoma Conference. Featuring perspectives from Drs Jeremy Abramson, Brad S Kahl, John P Leonard and Julie M Vose. | For more information, visit: http://www.researchtopractice.com/Lymphomas18/MCL

An Audio Review Journal for Nurses – Lymphoma and Multiple Myeloma Edition - Featuring interviews with Amy Goodrich, CRNP-AC, John P Leonard, MD, Jonathan L Kaufman, MD, Kevin Brigle, PhD, ANP conducted by Neil Love, MD. Produced by Research To Practice.

An Audio Review Journal for Nurses – Lymphoma and Multiple Myeloma Edition - Featuring interviews with Amy Goodrich, CRNP-AC, John P Leonard, MD, Jonathan L Kaufman, MD, Kevin Brigle, PhD, ANP conducted by Neil Love, MD. Produced by Research To Practice.

An Audio Review Journal for Nurses – Lymphoma and Multiple Myeloma Edition - Featuring interviews with Amy Goodrich, CRNP-AC, John P Leonard, MD, Jonathan L Kaufman, MD, Kevin Brigle, PhD, ANP conducted by Neil Love, MD. Produced by Research To Practice.

An Audio Review Journal for Nurses – Lymphoma and Multiple Myeloma Edition - Featuring interviews with Amy Goodrich, CRNP-AC, John P Leonard, MD, Jonathan L Kaufman, MD, Kevin Brigle, PhD, ANP conducted by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Featuring interviews with Anas Younes, MD, B Douglas Smith, MD, Rafael Fonseca, MD and John P Leonard, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with John P Leonard, MD conducted by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Proceedings from a Clinical Investigator Think Tank featuring Jonathan W Friedberg, MD, MMSc, Steven M Horwitz, MD, Brad S Kahl, MD, Mark S Kaminski, MD, John P Leonard, MD, Craig Moskowitz, MD, Mitchell R Smith, MD, PhD and Anas Younes, MD. Moderated by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Proceedings from a Clinical Investigator Think Tank featuring Jonathan W Friedberg, MD, MMSc, Steven M Horwitz, MD, Brad S Kahl, MD, Mark S Kaminski, MD, John P Leonard, MD, Craig Moskowitz, MD, Mitchell R Smith, MD, PhD and Anas Younes, MD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

What clinicians want to know: addressing the most common questions and controversies in the current clinical management of select hematologic cancers. Featuring interviews with Antonio Palumbo, MD, Susan M O’Brien, MD, John P Leonard, MD, Lauren C Pinter-Brown, MD and Sergio Giralt, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Recent Developments in Clinical and Translational Research in NHL and CLL. Proceedings from a Clinical Investigator Think Tank featuring Bruce D Cheson, MD, Francine Foss, MD, Jonathan W Friedberg, MD, MMSc, Steven M Horwitz, MD, Brad S Kahl, MD, John P Leonard, MD, Peter McLaughlin, MD and Andrew D Zelenetz, MD, PhD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Cancer Conference Update - Discussion of 67 Presentations and Posters from the 2011 American Society of Clinical Oncology Meeting in Chicago. Featuring interviews with Jedd D Wolchok, MD, PhD, John P Leonard, MD, William K Oh, MD, Leonard B Saltz, MD, Edward S Kim, MD, Sergio Giralt, MD, Julie R Gralow, MD, Susan M O’Brien, MD and Beth Y Karlan, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Interview with John P Leonard, MD conducted by Neil Love, MD. Produced by Research To Practice.

Interview with John P Leonard, MD conducted by Neil Love, MD. Produced by Research To Practice.

An Audio Review Journal for Nurses featuring interviews with John P Leonard, MD, Rafael Fonseca, MD, Kena C Miller, MSN, FNP and Mollie Moran, MSN, CNP, AOCNP conducted by Neil Love, MD. CNE Information and Program PDF. Produced by Research To Practice.

An Audio Review Journal for Nurses. Management of Non-Hodgkin’s Lymphomas and Multiple Myeloma. Interview with John P Leonard, MD conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/CACU210 – Interview with John P Leonard, MD conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/CACU210 – Cancer Conference Update - Discussion of 67 Presentations and Posters from the 2010 Annual American Society of Clinical Oncology Meeting in Chicago, Illinois. Featuring interviews with Steven J O’Day, MD, Daniel J George, MD, John P Leonard, MD, Hagop M Kantarjian, MD, Ravi Vij, MD, David R Spriggs, MD, Eric P Winer, MD, Corey J Langer, MD and Richard M Goldberg, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

ResearchToPractice.com/VPNHL10 - Case 8 from the practice of Neil Morganstein, MD presented to John P Leonard, MD. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPNHL10 - Case 9 from the practice of Neil Morganstein, MD presented to John P Leonard, MD. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPNHL10 - Case 1 from the practice of Neil Morganstein, MD presented to John P Leonard, MD. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPNHL10 - Case 2 from the practice of Neil Morganstein, MD presented to John P Leonard, MD. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPNHL10 - Case 6 from the practice of Neil Morganstein, MD presented to John P Leonard, MD. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPNHL10 - Case 7 from the practice of Neil Morganstein, MD presented to John P Leonard, MD. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPNHL10 – A case-based discussion on the management of breast cancer featuring interviews with John P Leonard, MD and Neil Morganstein, MD; and Margaret A Deutsch, MD and Bruce D Cheson, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

ResearchToPractice.com/BCUS110 – Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Featuring interviews with John P Leonard, MD, David P Steensma, MD, Anas Younes, MD and Paul G Richardson, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

ResearchToPractice.com/HOU210 – Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with John P Leonard, MD conducted by Neil Love, MD. Produced by Research To Practice.

www.CancerConferenceUpdate.com – Audio Reviews of Key Presentations and Posters from Important Scientific Meetings. Presentations from the 2008 American Society of Clinical Oncology Meeting in Chicago, Illinois. Interviews conducted by Neil Love, MD. Produced by Research To Practice.